Ocular Therapeutix, Inc (OCUL) is the 68th largest of 300 Biotechnology companies by market capitalisation, at 2.41 Bn, behind HUTCHMED (China) Ltd at 2.43 Bn. The table below compares all 300 on 8 financial metrics.
| # | Ticker | Company | match | industry_code | industry_group | industry_group_code | Market Capitalization | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AMGN | Amgen Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 236.84 Bn | 0.00 Mn | 6.22 | 222.85 Bn |
| 2 | GILD | Gilead Sciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 187.61 Bn | 0.00 Mn | 6.16 | 184.43 Bn |
| 3 | VRTX | Vertex Pharmaceuticals Inc / Ma | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 140.22 Bn | 0.00 Mn | 11.14 | 132.37 Bn |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 86.04 Bn | 0.00 Mn | 5.54 | 78.05 Bn |
| 5 | ARGX | Argenx Se | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 63.70 Bn | 0.00 Mn | 12.19 | 58.52 Bn |
| 6 | MRNA | Moderna, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 57.56 Bn | 0.00 Mn | 25.83 | 52.42 Bn |
| 7 | ALNY | Alnylam Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 35.63 Bn | 0.00 Mn | 7.42 | 32.32 Bn |
| 8 | BIIB | Biogen Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 32.64 Bn | 0.00 Mn | 3.25 | 31.35 Bn |
| 9 | INSM | INSMED Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 27.73 Bn | 0.00 Mn | 24.37 | 26.57 Bn |
| 10 | BNTX | BioNTech SE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 25.27 Bn | 0.00 Mn | 8.17 | 11.62 Bn |
| 11 | ROIV | Roivant Sciences Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 24.89 Bn | 0.00 Mn | 2,278.53 | 24.89 Bn |
| 12 | ASND | Ascendis Pharma A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 16.26 Bn | 0.00 Mn | 13.32 | 15.32 Bn |
| 13 | MDGL | Madrigal Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.93 Bn | 0.00 Mn | 12.41 | 15.09 Bn |
| 14 | BBIO | BridgeBio Pharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 14.58 Bn | 0.00 Mn | 20.45 | 13.86 Bn |
| 15 | SMMT | Summit Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 13.49 Bn | — | — | 12.80 Bn |
| 16 | HALO | Halozyme Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.89 Bn | 0.00 Mn | 7.75 | 12.66 Bn |
| 17 | BMRN | Biomarin Pharmaceutical Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.85 Bn | 0.00 Mn | 3.77 | 11.97 Bn |
| 18 | ARWR | Arrowhead Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.17 Bn | 0.00 Mn | 18.18 | 10.57 Bn |
| 19 | PRAX | Praxis Precision Medicines, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.28 Bn | 0.00 Mn | — | 9.52 Bn |
| 20 | APGE | Apogee Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.18 Bn | 0.00 Mn | — | 9.20 Bn |
| 21 | IONS | Ionis Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.68 Bn | 0.00 Mn | 11.07 | 7.62 Bn |
| 22 | PTGX | Protagonist Therapeutics, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.64 Bn | 0.00 Mn | 34.20 | 9.64 Bn |
| 23 | PCVX | Vaxcyte, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.91 Bn | 0.00 Mn | — | 8.91 Bn |
| 24 | IBRX | ImmunityBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.59 Bn | 0.00 Mn | 51.84 | 8.24 Bn |
| 25 | IMVT | Immunovant, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.05 Bn | 0.00 Mn | — | 8.05 Bn |
| 26 | TGTX | Tg Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.99 Bn | 0.00 Mn | 9.99 | 7.31 Bn |
| 27 | ABVX | Abivax S.A. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.91 Bn | 0.00 Mn | — | 7.91 Bn |
| 28 | SYRE | Spyre Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.43 Bn | 0.00 Mn | — | 7.43 Bn |
| 29 | SRRK | Scholar Rock Holding Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.23 Bn | 0.00 Mn | — | 7.23 Bn |
| 30 | RYTM | Rhythm Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.04 Bn | 0.00 Mn | 29.36 | 6.71 Bn |
| 31 | BLRX | BioLineRx Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.68 Bn | 0.00 Mn | 4,799.49 | 6.68 Bn |
| 32 | CGON | CG Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.55 Bn | 0.00 Mn | 1,051.38 | 6.55 Bn |
| 33 | MIRM | Mirum Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.41 Bn | 0.00 Mn | 10.36 | 5.97 Bn |
| 34 | KNSA | Kiniksa Pharmaceuticals International, plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.14 Bn | 0.00 Mn | 7.31 | 5.62 Bn |
| 35 | COGT | Cogent Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.97 Bn | 0.00 Mn | — | 5.97 Bn |
| 36 | XENE | Xenon Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.94 Bn | 0.00 Mn | — | 5.94 Bn |
| 37 | ORKA | Oruka Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.88 Bn | — | — | 4.15 Bn |
| 38 | DBVT | DBV Technologies S.A. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.81 Bn | 0.00 Mn | 1,158.34 | 5.64 Bn |
| 39 | PTCT | Ptc Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.80 Bn | 0.00 Mn | 5.75 | 3.57 Bn |
| 40 | LGND | Ligand Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.75 Bn | 0.00 Mn | 19.78 | 4.39 Bn |
| 41 | GRFS | Grifols SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.31 Bn | 0.00 Mn | 0.32 | 4.15 Bn |
| 42 | CELC | Celcuity Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.26 Bn | 0.00 Mn | — | 5.26 Bn |
| 43 | ERAS | Erasca, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.08 Bn | 0.00 Mn | — | 5.08 Bn |
| 44 | RADX | Radiopharm Theranostics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.36 Bn | 0.00 Mn | 20,980.03 | 4.36 Bn |
| 45 | DNLI | Denali Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.17 Bn | 0.00 Mn | 1,156.51 | 4.17 Bn |
| 46 | DNTH | Dianthus Therapeutics, Inc. /DE/ | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.06 Bn | — | — | 3.66 Bn |
| 47 | DYN | Dyne Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.05 Bn | 0.00 Mn | — | 4.05 Bn |
| 48 | TLX | Telix Pharmaceuticals Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.03 Bn | — | — | 3.74 Bn |
| 49 | VKTX | Viking Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.99 Bn | 0.00 Mn | — | 3.99 Bn |
| 50 | RLAY | Relay Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.84 Bn | 0.00 Mn | 370.62 | 3.84 Bn |
| 51 | AMLX | Amylyx Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.76 Bn | 0.00 Mn | — | 3.76 Bn |
| 52 | RCUS | Arcus Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.73 Bn | 0.00 Mn | 31.88 | 3.03 Bn |
| 53 | IDYA | IDEAYA Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.66 Bn | 0.00 Mn | 15.65 | 2.84 Bn |
| 54 | ABCL | AbCellera Biologics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.49 Bn | 0.00 Mn | 52.76 | 3.49 Bn |
| 55 | TNGX | Tango Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.38 Bn | 0.00 Mn | 62.75 | 2.36 Bn |
| 56 | ARQT | Arcutis Biotherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.11 Bn | 0.00 Mn | 6.70 | 2.87 Bn |
| 57 | IRON | Disc Medicine, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.07 Bn | 0.00 Mn | — | 3.07 Bn |
| 58 | CLDX | Celldex Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.06 Bn | 0.00 Mn | 19,361.47 | 3.06 Bn |
| 59 | IMNM | Immunome Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.05 Bn | 0.00 Mn | 593.06 | 2.53 Bn |
| 60 | MBX | MBX Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.93 Bn | 0.00 Mn | — | 2.93 Bn |
| 61 | ZLAB | Zai Lab Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.90 Bn | 0.00 Mn | 6.45 | 2.19 Bn |
| 62 | NRIX | Nurix Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.85 Bn | 0.00 Mn | 77.53 | 2.41 Bn |
| 63 | SLS | SELLAS Life Sciences Group, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.64 Bn | 0.00 Mn | — | 2.64 Bn |
| 64 | VERA | Vera Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.56 Bn | 0.00 Mn | — | 2.56 Bn |
| 65 | BCRX | Biocryst Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.53 Bn | 0.00 Mn | 4.72 | 2.17 Bn |
| 66 | NKTR | Nektar Therapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.44 Bn | 0.00 Mn | 44.76 | 1.76 Bn |
| 67 | HCM | HUTCHMED (China) Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.43 Bn | 0.00 Mn | 3.41 | 2.43 Bn |
| 68 | OCUL | Ocular Therapeutix, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.41 Bn | 0.00 Mn | 46.37 | 2.41 Bn |
| 69 | VRDN | Viridian Therapeutics, Inc.\DE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.40 Bn | 0.00 Mn | 33.72 | 2.40 Bn |
| 70 | BHVN | Biohaven Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.35 Bn | 0.00 Mn | — | 2.08 Bn |
| 71 | XTLB | Xtl Biopharmaceuticals Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.25 Bn | 0.00 Mn | — | 2.25 Bn |
| 72 | RAPP | Rapport Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.23 Bn | 0.00 Mn | 111.66 | 2.23 Bn |
| 73 | KOD | Kodiak Sciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.23 Bn | 0.00 Mn | — | 2.23 Bn |
| 74 | URGN | UroGen Pharma Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.21 Bn | 0.00 Mn | 11.72 | 2.10 Bn |
| 75 | GMAB | Genmab A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.19 Bn | 0.00 Mn | 0.34 | 0.69 Bn |
| 76 | ADMA | Adma Biologics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.17 Bn | 0.00 Mn | 4.24 | 2.03 Bn |
| 77 | ZYME | Zymeworks Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.15 Bn | 0.00 Mn | 58.00 | 1.88 Bn |
| 78 | PHVS | Pharvaris N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.14 Bn | 0.00 Mn | — | 1.77 Bn |
| 79 | ZBIO | Zenas BioPharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.07 Bn | 0.00 Mn | 2,069.45 | 2.07 Bn |
| 80 | XNCR | Xencor Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.02 Bn | 0.00 Mn | 19.20 | 1.64 Bn |
| 81 | AGIO | Agios Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.98 Bn | 0.00 Mn | 20.16 | 1.98 Bn |
| 82 | STOK | Stoke Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.97 Bn | 0.00 Mn | 71.43 | 1.68 Bn |
| 83 | RXRX | Recursion Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.95 Bn | 0.00 Mn | 35.48 | 1.40 Bn |
| 84 | VIR | Vir Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.92 Bn | 0.00 Mn | 6.34 | 1.92 Bn |
| 85 | INBX | Inhibrx Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.91 Bn | 0.00 Mn | 1,466.08 | 1.91 Bn |
| 86 | IMCR | Immunocore Holdings plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.88 Bn | 0.00 Mn | 4.37 | 1.00 Bn |
| 87 | LKFT | Lakefront Biotherapeutics NV | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.88 Bn | 0.00 Mn | 1.63 | 1.88 Bn |
| 88 | TYRA | Tyra Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.88 Bn | 0.00 Mn | — | 1.88 Bn |
| 89 | SNDX | Syndax Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.85 Bn | 0.00 Mn | 7.33 | 1.30 Bn |
| 90 | SCNI | Scinai Immunotherapeutics Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.78 Bn | 0.00 Mn | 1,030.81 | 1.77 Bn |
| 91 | CMPS | COMPASS Pathways plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.77 Bn | 0.00 Mn | — | 1.77 Bn |
| 92 | DMRA | Damora Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.70 Bn | 0.00 Mn | — | 1.16 Bn |
| 93 | GHRS | GH Research PLC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.69 Bn | 0.00 Mn | — | 1.33 Bn |
| 94 | NVAX | Novavax Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.69 Bn | 0.00 Mn | 4.08 | 0.97 Bn |
| 95 | SEPN | Septerna, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.66 Bn | 0.00 Mn | 16.81 | 1.66 Bn |
| 96 | ANAB | Anaptysbio, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.64 Bn | 0.00 Mn | 8.21 | 1.35 Bn |
| 97 | RARE | Ultragenyx Pharmaceutical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.61 Bn | 0.00 Mn | 2.25 | 1.32 Bn |
| 98 | ATAI | AtaiBeckley Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.59 Bn | 0.00 Mn | 525.18 | 1.59 Bn |
| 99 | BCAX | Bicara Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | 0.00 Mn | — | 1.58 Bn |
| 100 | FBRX | Forte Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | 0.00 Mn | — | 1.23 Bn |
| 101 | AAPG | Ascentage Pharma Group International | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.57 Bn | 0.00 Mn | 20.12 | 1.29 Bn |
| 102 | MAZE | Maze Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.55 Bn | 0.00 Mn | 77.55 | 1.55 Bn |
| 103 | ANRO | Alto Neuroscience, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.53 Bn | 0.00 Mn | — | 1.53 Bn |
| 104 | AVBP | ArriVent BioPharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.46 Bn | 0.00 Mn | — | 1.46 Bn |
| 105 | REPL | Replimune Group, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.46 Bn | 0.00 Mn | — | 1.46 Bn |
| 106 | ALMS | Alumis Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.44 Bn | 0.00 Mn | 173.22 | 0.94 Bn |
| 107 | GLUE | Monte Rosa Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.43 Bn | 0.00 Mn | 49.91 | 0.80 Bn |
| 108 | ABSI | Absci Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.41 Bn | 0.00 Mn | 904.38 | 1.21 Bn |
| 109 | ORIC | Oric Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.38 Bn | 0.00 Mn | — | 1.38 Bn |
| 110 | OMER | Omeros Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.38 Bn | 0.00 Mn | 35.93 | 1.38 Bn |
| 111 | CGEM | Cullinan Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.37 Bn | 0.00 Mn | — | 1.37 Bn |
| 112 | SVRA | Savara Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.35 Bn | 0.00 Mn | — | 1.35 Bn |
| 113 | VOR | Vor Biopharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.34 Bn | 0.00 Mn | — | 1.34 Bn |
| 114 | CRVS | Corvus Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.34 Bn | 0.00 Mn | — | 1.12 Bn |
| 115 | JANX | Janux Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | 0.00 Mn | 52.66 | 1.26 Bn |
| 116 | MNKD | Mannkind Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | 0.00 Mn | 3.19 | 1.14 Bn |
| 117 | JBIO | Jade Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.22 Bn | 0.00 Mn | — | 1.22 Bn |
| 118 | CLYM | Climb Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.20 Bn | 0.00 Mn | — | 1.20 Bn |
| 119 | MLTX | MoonLake Immunotherapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.10 Bn | 0.00 Mn | — | 0.57 Bn |
| 120 | OKYO | OKYO Pharma Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.06 Bn | 0.00 Mn | — | 1.06 Bn |
| 121 | ABUS | Arbutus Biopharma Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.01 Bn | 0.00 Mn | 5.58 | 0.92 Bn |
| 122 | GERN | Geron Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.01 Bn | 0.00 Mn | 4.14 | 0.71 Bn |
| 123 | MNPR | Monopar Therapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.00 Bn | 0.00 Mn | — | 0.95 Bn |
| 124 | WVE | Wave Life Sciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.00 Bn | 0.00 Mn | 15.23 | 0.63 Bn |
| 125 | ANNX | Annexon, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.98 Bn | 0.00 Mn | — | 0.98 Bn |
| 126 | ARDX | Ardelyx, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.93 Bn | 0.00 Mn | 2.06 | 0.65 Bn |
| 127 | RIGL | Rigel Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.90 Bn | 0.00 Mn | 3.27 | 0.81 Bn |
| 128 | STTK | Shattuck Labs, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.88 Bn | 0.00 Mn | 882.50 | 0.88 Bn |
| 129 | TBPH | Theravance Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.88 Bn | 0.00 Mn | 8.46 | 0.49 Bn |
| 130 | ACRS | Aclaris Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.85 Bn | 0.00 Mn | 103.94 | 0.85 Bn |
| 131 | AVTX | Avalo Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.84 Bn | 0.00 Mn | — | 0.84 Bn |
| 132 | CTMX | CytomX Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.79 Bn | 0.00 Mn | 43.18 | 0.46 Bn |
| 133 | PHAR | Pharming Group N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.78 Bn | 0.00 Mn | 2.35 | 0.62 Bn |
| 134 | ZURA | Zura Bio Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.76 Bn | 0.00 Mn | — | 0.76 Bn |
| 135 | BBOT | BridgeBio Oncology Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.72 Bn | 0.00 Mn | — | 0.49 Bn |
| 136 | AURA | Aura Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.71 Bn | 0.00 Mn | — | 0.64 Bn |
| 137 | IRWD | Ironwood Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.70 Bn | 0.00 Mn | 1.81 | 0.62 Bn |
| 138 | SLN | Silence Therapeutics plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.69 Bn | 0.00 Mn | 1,122.93 | 0.62 Bn |
| 139 | ASMB | Assembly Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.69 Bn | 0.00 Mn | 9.21 | 0.37 Bn |
| 140 | CBIO | Crescent Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.65 Bn | 0.00 Mn | 627.98 | 0.48 Bn |
| 141 | OCS | Oculis Holding AG | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.64 Bn | -0.37 Mn | — | 0.35 Bn |
| 142 | CTNM | Contineum Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.64 Bn | 0.00 Mn | — | 0.64 Bn |
| 143 | ALT | Altimmune, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | 0.00 Mn | — | 0.61 Bn |
| 144 | ARVN | Arvinas, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | 0.00 Mn | 1.92 | 0.04 Bn |
| 145 | VALN | Valneva SE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | 555.46 Mn | 3.50 | 0.44 Bn |
| 146 | OABI | OmniAb, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | 0.00 Mn | 15.14 | 0.53 Bn |
| 147 | TECX | Tectonic Therapeutic, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.57 Bn | 0.00 Mn | — | 0.57 Bn |
| 148 | SGMT | Sagimet Biosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.57 Bn | 0.00 Mn | — | 0.57 Bn |
| 149 | PRLD | Prelude Therapeutics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.54 Bn | 0.00 Mn | 24.04 | 0.26 Bn |
| 150 | IMUX | Immunic, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.54 Bn | 0.00 Mn | — | 0.54 Bn |
| 151 | PRTA | Prothena Corp Public Ltd Co | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.51 Bn | 0.00 Mn | 9.30 | 0.22 Bn |
| 152 | ANL | Adlai Nortye Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.50 Bn | 0.00 Mn | 78.36 | 0.27 Bn |
| 153 | RLMD | Relmada Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | 0.00 Mn | — | 0.49 Bn |
| 154 | KMDA | Kamada Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | 0.00 Mn | 2.54 | 0.42 Bn |
| 155 | CCCC | C4 Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | 0.00 Mn | 13.89 | 0.23 Bn |
| 156 | PBYI | Puma Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.48 Bn | 0.00 Mn | 2.09 | 0.39 Bn |
| 157 | RZLT | Rezolute, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.48 Bn | 0.00 Mn | — | 0.48 Bn |
| 158 | NEUP | Neuphoria Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | 0.00 Mn | — | 0.45 Bn |
| 159 | AVIR | Atea Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | 0.00 Mn | — | 0.46 Bn |
| 160 | DRUG | Bright Minds Biosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | 0.00 Mn | — | 0.24 Bn |
| 161 | CMPX | Compass Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | 0.00 Mn | — | 0.45 Bn |
| 162 | ARCT | Arcturus Therapeutics Holdings Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | 0.00 Mn | 15.29 | 0.26 Bn |
| 163 | EVMN | Evommune, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | 0.00 Mn | 43.76 | 0.24 Bn |
| 164 | BIOA | BioAge Labs, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.43 Bn | 0.00 Mn | 41.22 | 0.43 Bn |
| 165 | ENTA | Enanta Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.41 Bn | 0.00 Mn | 6.30 | 0.22 Bn |
| 166 | LRMR | Larimar Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | 0.00 Mn | — | 0.24 Bn |
| 167 | EYPT | EyePoint, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | 0.00 Mn | 141.96 | 0.22 Bn |
| 168 | WHWK | Whitehawk Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | 0.00 Mn | — | 0.38 Bn |
| 169 | CATX | Perspective Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.37 Bn | 0.00 Mn | — | 0.37 Bn |
| 170 | FHTX | Foghorn Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.35 Bn | 0.00 Mn | 9.46 | 0.28 Bn |
| 171 | ELDN | Eledon Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | 0.00 Mn | — | 0.34 Bn |
| 172 | AGEN | Agenus Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | 0.00 Mn | 2.57 | 0.34 Bn |
| 173 | STRO | Sutro Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | 0.00 Mn | 3.76 | 0.17 Bn |
| 174 | UPB | Upstream Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.33 Bn | 0.00 Mn | 105.92 | 0.33 Bn |
| 175 | EPRX | Eupraxia Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | — | 0.30 Bn |
| 176 | TRDA | Entrada Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | 64.60 | 0.30 Bn |
| 177 | GALT | Galectin Therapeutics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | — | 0.30 Bn |
| 178 | BCYC | Bicycle Therapeutics Plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | 4.88 | 0.30 Bn |
| 179 | SABS | SAB Biotherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | — | 0.30 Bn |
| 180 | ACIU | AC Immune SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | 0.00 Mn | 13.11 | 0.29 Bn |
| 181 | ALEC | Alector, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | 0.00 Mn | 20.42 | 0.11 Bn |
| 182 | ALXO | Alx Oncology Holdings Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | 0.00 Mn | — | 0.27 Bn |
| 183 | MGNX | Macrogenics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | 0.00 Mn | 1.62 | 0.16 Bn |
| 184 | CYDY | CytoDyn Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | 0.00 Mn | — | 0.27 Bn |
| 185 | AVXL | Anavex Life Sciences Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | 0.00 Mn | — | 0.15 Bn |
| 186 | ANTX | AN2 Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | 0.00 Mn | — | 0.26 Bn |
| 187 | CAMP | Camp4 Therapeutics Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | 0.00 Mn | 61.97 | 0.26 Bn |
| 188 | SRZN | Surrozen, Inc./DE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | 0.00 Mn | 22.58 | 0.26 Bn |
| 189 | IVVD | Invivyd, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | 0.00 Mn | 4.60 | 0.10 Bn |
| 190 | FIXX | Q32 Bio Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | 0.00 Mn | — | 0.15 Bn |
| 191 | PYXS | Pyxis Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | 0.00 Mn | 18.24 | 0.22 Bn |
| 192 | EQ | Equillium, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | 0.00 Mn | — | 0.25 Bn |
| 193 | NMRA | Neumora Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | 0.00 Mn | — | 0.24 Bn |
| 194 | YDES | YD Bio Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | 0.00 Mn | 287.04 | 0.24 Bn |
| 195 | CGEN | Compugen Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | 0.00 Mn | 3.26 | 0.16 Bn |
| 196 | GLSI | Greenwich LifeSciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | 0.00 Mn | — | 0.23 Bn |
| 197 | FTH | Faeth Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | 0.00 Mn | — | 0.23 Bn |
| 198 | ABOS | Acumen Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | 0.00 Mn | — | 0.22 Bn |
| 199 | KROS | Keros Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | 0.00 Mn | 6.75 | -0.04 Bn |
| 200 | PRQR | ProQR Therapeutics N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | 0.00 Mn | 10.22 | 0.08 Bn |
| 201 | CHRS | Coherus Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | 0.00 Mn | 4.30 | 0.11 Bn |
| 202 | PEPG | PepGen Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | 0.00 Mn | — | 0.22 Bn |
| 203 | KRRO | Korro Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 0.00 Mn | 90.24 | 0.10 Bn |
| 204 | ADAG | Adagene Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 0.00 Mn | 32.66 | 0.21 Bn |
| 205 | PLX | Protalix BioTherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 0.00 Mn | 2.64 | 0.17 Bn |
| 206 | ARMP | Armata Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 0.00 Mn | — | 0.18 Bn |
| 207 | ADCT | ADC Therapeutics SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 0.00 Mn | 2.74 | -0.01 Bn |
| 208 | ORMP | Oramed Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | 0.00 Mn | — | 0.20 Bn |
| 209 | NBP | NovaBridge Biosciences | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | 0.00 Mn | — | 0.20 Bn |
| 210 | QNCX | Quince Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | 0.00 Mn | — | 0.20 Bn |
| 211 | IPHA | Innate Pharma SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | 0.00 Mn | 60.95 | 0.19 Bn |
| 212 | XLO | Xilio Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | 0.00 Mn | 2.77 | 0.04 Bn |
| 213 | OKUR | OnKure Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | 0.00 Mn | — | 0.00 Bn |
| 214 | CUE | Cue Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | 0.00 Mn | 7.82 | 0.16 Bn |
| 215 | NGEN | Nervgen Pharma Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | 0.00 Mn | — | 0.17 Bn |
| 216 | MIST | Milestone Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | — | — | 0.00 Bn |
| 217 | MOLN | Molecular Partners Ag | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | 0.00 Mn | 28.43 | 0.16 Bn |
| 218 | RANI | Rani Therapeutics Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | 0.00 Mn | 33.16 | 0.16 Bn |
| 219 | ENTX | Entera Bio Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | 0.00 Mn | — | 0.14 Bn |
| 220 | MDWD | MediWound Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | 0.00 Mn | 12.75 | 0.12 Bn |
| 221 | IFRX | InflaRx N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | 0.00 Mn | 1,899.21 | -0.03 Bn |
| 222 | SPRB | Spruce Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | 0.00 Mn | — | 0.14 Bn |
| 223 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | — | — | -0.02 Bn |
| 224 | UNCY | Unicycive Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | 0.00 Mn | — | 0.14 Bn |
| 225 | IBIO | iBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | 0.00 Mn | 1,373.59 | 0.14 Bn |
| 226 | HURA | TuHURA Biosciences, Inc./NV | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | 0.00 Mn | — | 0.14 Bn |
| 227 | MSLE | Satellos Bioscience Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | 0.00 Mn | — | 0.13 Bn |
| 228 | RFL | Rafael Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | 0.00 Mn | 134.35 | 0.13 Bn |
| 229 | NRXP | NRX Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | 0.00 Mn | 37.91 | 0.10 Bn |
| 230 | CNTB | Connect Biopharma Holdings Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | 0.00 Mn | 41.43 | 0.12 Bn |
| 231 | BDTX | Black Diamond Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | 0.00 Mn | — | 0.01 Bn |
| 232 | TLSA | Tiziana Life Sciences Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | 0.00 Mn | — | 0.12 Bn |
| 233 | PMN | ProMIS Neurosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | 0.00 Mn | — | 0.06 Bn |
| 234 | INO | Inovio Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | 0.00 Mn | — | 0.11 Bn |
| 235 | GNLX | GENELUX Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | 0.00 Mn | — | 0.11 Bn |
| 236 | COYA | Coya Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | 0.00 Mn | 13.34 | 0.06 Bn |
| 237 | ONCY | Oncolytics Biotech Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | 0.00 Mn | — | 0.10 Bn |
| 238 | PLYX | Polaryx Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | 0.00 Mn | — | 0.08 Bn |
| 239 | RLYB | Rallybio Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | 0.00 Mn | 148.74 | 0.10 Bn |
| 240 | OTLK | Outlook Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | — | 0.08 Bn |
| 241 | KZIA | Kazia Therapeutics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | — | — | 0.09 Bn |
| 242 | KLRS | Kalaris Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | — | 0.09 Bn |
| 243 | ALDX | Aldeyra Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | — | 0.09 Bn |
| 244 | ACRV | Acrivon Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | — | 0.09 Bn |
| 245 | PYPD | PolyPid Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | — | 0.08 Bn |
| 246 | RVRC | Revium Rx. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | — | 0.09 Bn |
| 247 | FBIO | Fortress Biotech, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | 1.26 | -0.11 Bn |
| 248 | CTOR | Citius Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 0.00 Mn | 55.22 | 0.09 Bn |
| 249 | ATHE | Alterity Therapeutics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 0.00 Mn | — | 0.06 Bn |
| 250 | DWTX | Dogwood Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 0.00 Mn | — | 0.08 Bn |
| 251 | MAIA | MAIA Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 0.00 Mn | — | 0.05 Bn |
| 252 | GANX | Gain Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 0.00 Mn | — | 0.08 Bn |
| 253 | INDP | Indaptus Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 0.00 Mn | — | 0.06 Bn |
| 254 | CRDF | Cardiff Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 0.00 Mn | 127.37 | 0.07 Bn |
| 255 | TELO | Telomir Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 0.00 Mn | — | 0.07 Bn |
| 256 | SPRO | Spero Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 0.00 Mn | 1.49 | 0.02 Bn |
| 257 | XBIT | XBiotech Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 0.00 Mn | — | 0.07 Bn |
| 258 | HRTX | Heron Therapeutics, Inc. /De/ | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 0.00 Mn | 0.44 | 0.02 Bn |
| 259 | ALGS | Aligos Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 0.00 Mn | 17.15 | 0.03 Bn |
| 260 | SCYX | Scynexis Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 0.00 Mn | 3.30 | -0.05 Bn |
| 261 | RNTX | Rein Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 0.00 Mn | — | 0.06 Bn |
| 262 | MCRB | Seres Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | 28.76 | 0.05 Bn |
| 263 | IMMP | IMMUTEP Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | 5.23 | 0.00 Bn |
| 264 | TIL | Instil Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | — | 0.05 Bn |
| 265 | IBO | Impact Biomedical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | 1,453.43 | 0.05 Bn |
| 266 | PTN | Palatin Technologies Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | 3.93 | 0.05 Bn |
| 267 | ATYR | aTYR PHARMA INC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | 294.15 | -0.01 Bn |
| 268 | NMAD | Nomad Power Solutions, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | — | 0.05 Bn |
| 269 | ELTX | Elicio Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | — | 0.02 Bn |
| 270 | HOWL | Werewolf Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | 2.18 | 0.05 Bn |
| 271 | SER | Serina Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | 334.00 | 0.02 Bn |
| 272 | EDSA | Edesa Biotech, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | — | 0.04 Bn |
| 273 | MREO | Mereo BioPharma Group plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | 83.35 | 0.04 Bn |
| 274 | NXTC | NextCure, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | — | 0.04 Bn |
| 275 | IMA | ImageneBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | — | — | -0.10 Bn |
| 276 | APLM | Apollomics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | 4.72 | 0.04 Bn |
| 277 | FLNA | Filana Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | — | 0.04 Bn |
| 278 | LITS | Lite Strategy, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | — | 0.03 Bn |
| 279 | KYNB | Kyntra Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 4.46 | 0.03 Bn |
| 280 | CNTX | Context Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 281 | BHST | Bioharvest Sciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 0.94 | 0.02 Bn |
| 282 | ATNM | Actinium Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 0.93 | 0.03 Bn |
| 283 | BETRF | BetterLife Pharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 284 | BRNS | Barinthus Biotherapeutics plc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 285 | KAPA | Kairos Pharma, LTD. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 0.35 | 0.03 Bn |
| 286 | ADIL | Adial Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 287 | IGC | IGC Pharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 93.50 | 0.03 Bn |
| 288 | CLRB | Cellectar Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 289 | TAOX | TAO Synergies Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 36.76 | 0.03 Bn |
| 290 | RAPH | Raphael Pharmaceutical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 291 | VRXA | Veraxa Biotech AG - Post de-SPAC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | 755.61 | 0.02 Bn |
| 292 | NNVC | Nanoviricides, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | 0.02 Bn |
| 293 | ABVC | Abvc Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | 0.02 Bn |
| 294 | LTRN | Lantern Pharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | 0.02 Bn |
| 295 | GRDX | GridAI Technologies Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | 239.09 | 0.02 Bn |
| 296 | EVAX | Evaxion A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | 2.65 | 0.02 Bn |
| 297 | JSPR | Jasper Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | 0.02 Bn |
| 298 | CNSY | Cerenome, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | 4.71 | 0.01 Bn |
| 299 | DYAI | Dyadic International Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | 4.87 | 0.02 Bn |
| 300 | CMMB | Chemomab Therapeutics Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | 0.01 Bn |